# Monopar Therapeutics (MNPR) — Earnings

MNPR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/mnpr/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$0.35 |
| EPS estimate | −$0.46 |
| EPS surprise | +23.63% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 12, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1645469/000143774925026042/mnpr20250630_10q.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 12, 2025 | −$0.46 | −$0.35 | 23.63% | — | — |
| Q1 2025 | May 13, 2025 | −$0.68 | −$0.38 | 44.12% | — | — |
| Q4 2024 | Mar 31, 2025 | −$0.38 | −$2.74 | -624.87% | — | — |
| Q3 2024 | Nov 8, 2024 | −$1.00 | −$0.37 | 62.81% | — | — |
| Q2 2024 | Aug 9, 2024 | −$0.50 | −$0.50 | 0.00% | — | — |
| Q1 2024 | May 9, 2024 | −$0.73 | −$0.50 | 31.03% | — | — |
| Q4 2023 | Mar 28, 2024 | −$0.82 | −$0.60 | 26.53% | — | — |
| Q3 2023 | Nov 9, 2023 | −$0.77 | −$0.70 | 8.70% | — | — |
| Q2 2023 | Aug 10, 2023 | −$0.92 | −$0.80 | 13.04% | — | — |
| Q1 2023 | May 11, 2023 | −$1.11 | −$0.95 | 14.41% | — | — |
| Q4 2022 | Mar 23, 2023 | −$1.03 | −$1.15 | -12.20% | — | — |
| Q3 2022 | Nov 10, 2022 | −$1.08 | −$0.95 | 12.30% | — | — |
| Q2 2022 | Aug 11, 2022 | −$1.03 | −$1.10 | -6.46% | — | — |
| Q1 2022 | May 12, 2022 | −$1.04 | −$0.95 | 8.65% | — | — |
| Q4 2021 | Mar 24, 2022 | −$0.97 | −$1.05 | -8.25% | — | — |
| Q3 2021 | Nov 12, 2021 | −$1.02 | −$1.00 | 1.96% | — | — |
| Q2 2021 | Aug 12, 2021 | −$0.94 | −$0.85 | 9.33% | — | — |
| Q1 2021 | May 13, 2021 | −$0.93 | −$0.80 | 14.28% | — | — |
| Q4 2020 | Mar 25, 2021 | −$0.93 | −$0.95 | -2.70% | — | — |
| Q3 2020 | Nov 12, 2020 | −$0.78 | −$0.75 | 4.25% | — | — |

## Frequently Asked Questions

### When did Monopar Therapeutics (MNPR) last report earnings?

Monopar Therapeutics last reported on Aug 12, 2025, covering fiscal Q2 2025.

### Did MNPR beat earnings estimates?

Yes. Monopar Therapeutics reported EPS of −$0.35 for Q2 2025 against a −$0.46 estimate — a 23.63% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).